For more detailed information on vaccinations, please see the CANIBD Vaccination Guide
Baseline ECG. In patients with pre-existing conditions, advice from a cardiologist should be sought.
Blood work (baseline CBC, renal and liver function) Opthalmic assessment in patients with a history of diabetes, uveitis or retinal disease.
Ensure all immunizations are current. Refer to CANIBD Vaccination Guidelines for further information14
Contraindications: Last 6 months myocardial infarction, unstable angina, pectoris, stroke, transient ischemic attack, decompensated heart failure, Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemake, immunocompromised, severe active infections, active malignancies
METHOD OF ADMINISTRATION
Oral
LOCATION
Home
DOSING
2 mg tablet once daily
Due to risk of transient decreases in heart rate, first dose cardiac monitoring recommended.
Hourly pulse and blood pressure for 4-hr period. ECG prior to and at the end of this 4-hr period is recommended.
Please refer to product monograph for additional information.
TIME REQUIRED
5 min
ROUTINE
MONITORING
Baseline bloodwork: Liver enzymes, ECG and ophthalmic evaluation. Follow up blood work as clinically indicated.
Blood pressure should be monitored during treatment and managed appropriately.
Patients with a history of diabetes mellitus, uveitis or retinal disease undergo follow up ophthalmologic evaluations while receiving therapy.